Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70700 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Tanja Mueller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scottish Government.
Abstract (Originalsprache)
Aims
The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland.
Methods
The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024. The National Systemic Anti‐Cancer Therapy (SACT) dataset was used to identify patients and obtain details on ICI treatments and patient characteristics. Additional data sources providing information on comorbidities were linked deterministically via a unique patient identifier. All analyses were descriptive.
Results
In total, 10 394 patients in Scotland initiated their first ICI treatment between 2018 and 2024; the number of patients initiating ICIs increased substantially year‐on‐year, from 764 patients in 2018 to 2233 patients in 2024. The most commonly prescribed ICI was pembrolizumab (56.8%, n = 5908), followed by nivolumab (16.4%, n = 1700) and atezolizumab (11.3%, n = 1170); treatment was most commonly initiated for lung and chest cancers (44.1%, n = 4585), skin cancer (18.8%, n = 1955) and urological cancers (14.8%, n = 1539). While the majority of patients (66.6%, n = 6923) initiated ICI monotherapy, combination therapies—most commonly ICI with chemotherapy (18.4%, n = 1910)—were also used. Overall, 6.6% of patients ( n = 681) were on treatment for more than 2 years.
Conclusions
With the continuous addition of new ICIs, alongside the ever‐expanding list of approved indications for their use, the observed increase in ICI use is expected to continue. This increasing use of ICIs may pose challenges to health services—for instance, an increase in immune‐related adverse effects—with potential implications for clinical practice and future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
- Public Health Scotland, Glasgow/Edinburgh, UK.
- NHS Greater Glasgow and Clyde, Glasgow, UK.
ORCID-Profile: Tanja Mueller, Amanj Kurdi
Förderung
- Scottish Government
Zitieren
APA
Mueller, T., Crearie, C., Lu, L., Pan, J., Sneden, F. N., Martin, D., Kurdi, A., Thomson, C. S., Clarke, J., & Bennie, M. (2026). Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70700
Vancouver
Mueller T, Crearie C, Lu L, Pan J, Sneden FN, Martin D, et al. Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70700
BibTeX
@article{Mueller2026,
author = {Mueller, Tanja and Crearie, Christine and Lu, Liya and Pan, Jiafeng and Sneden, Fraser N and Martin, David and Kurdi, Amanj and Thomson, Catherine S and Clarke, Julie and Bennie, Marion},
title = {Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70700}
}
EUVIMED